(Q36752023)

16 August 2017

1 reference

title

Treatment of acute myeloid leukemia in older patients (English)

1 reference

16 August 2017

main subject

acute myeloid leukemia

1 reference

Gail J Roboz

1

1 reference

16 August 2017

publication date

1 March 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

285-295

1 reference

16 August 2017

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Treatment of older patients with acute myeloid leukemia--new agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Fifty years of clinical research by the leukemia committee of the cancer and leukemia group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Low-dose cytosine arabinoside treatment for acute nonlymphocytic leukemia in elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Low-dose cytosine arabinoside in the myelodysplastic syndromes and acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

General approach to, and perspectives on clinical research in, older patients with newly diagnosed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Prognostic factors in elderly patients with acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Age and acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Cloretazine for the treatment of acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.3.285

21 January 2018

Identifiers

DOI

10.1586/14737140.7.3.285

1 reference

16 August 2017

1 reference